XENE announces pricing of public offering of common shares
Xenon Pharmaceuticals Announces Pricing of $60.0 Million Public Offering of Common Shares
GlobeNewswire GlobeNewswire•January 22, 2020
BURNABY, British Columbia, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $60.0 million. In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 562,500 common shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about January 27, 2020, subject to customary closing conditions.
Jefferies, Stifel and Guggenheim Securities are acting as joint book-running managers for the offering.
Bladerunner
